NCT00420381 2020-12-19Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal CancerEli Lilly and CompanyPhase 2 Completed28 enrolled 13 charts
NCT00309140 2020-06-26An Open Label Study of Oral Enzastaurin in Participants With CancerEli Lilly and CompanyPhase 2 Completed23 enrolled 13 charts